DaVita (NYSE:DVA – Get Free Report) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share guidance of 10.200-11.300 for the period, compared to the consensus earnings per share estimate of 11.030. The company issued revenue guidance of -.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on the stock. Barclays raised their price target on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 18th. StockNews.com raised shares of DaVita from a “hold” rating to a “buy” rating in a research note on Friday, April 25th. Cowen reaffirmed a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, DaVita currently has an average rating of “Hold” and a consensus price target of $166.33.
Read Our Latest Analysis on DVA
DaVita Price Performance
DaVita (NYSE:DVA – Get Free Report) last issued its earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, beating analysts’ consensus estimates of $1.75 by $0.25. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, sell-side analysts predict that DaVita will post 10.76 EPS for the current year.
About DaVita
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
- Five stocks we like better than DaVita
- 3 Small Caps With Big Return Potential
- Palantir’s Latest Deal Could Put a Freeze on Its Stock Price
- Best Stocks Under $10.00
- 4 Automaker Stocks React to Tariffs: Winners and Losers
- Trading Stocks: RSI and Why it’s Useful
- Here’s Why Call Option Traders Love Dutch Bros Stock
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.